¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ç׿ø.
  • heterologous antigen
    ÀÌÁ¾Ç׿ø
  • heterophil(e) antigen
    ÀÌÁ¾Ä£È­(¼º) Ç׿ø(¡­ù÷ê«).
  • heyman antigen
    ÇÏÀ̸¸ Ç׿ø, Heyman Ç׿ø
  • hidden antigen
    ÀºµÐÇ׿ø, ÀºÆóÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕÇ׿ø
  • histocompatibility antigen, major
    ÁÖÁ¶Á÷ÀûÇÕÇ׿ø
  • homologous antigen
    »óµ¿Ç׿ø.
  • i antigen
    i Ç׿ø
  • immunogen (antigen)
    ¸é¿ª¿ø(Øóæ¹ê«).
  • inaccessible antigen
    ¿ø°ÝÇ׿ø(êÀ̰ù÷ê«), ÀáÀçÇ׿ø.
  • incomplete antigen
    ºÒ¿ÏÀüÇ׿ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü¹éÇ÷±¸Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü¹éÇ÷±¸Ç׿ø
  • colloid antigen
    ¾Æ±³ÁúÇ׿ø
  • colonizing factor antigen (CFA)
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • common antigen
    °øÅëÇ׿ø(Íì÷×ù÷ê«).
  • complete antigen
    ¿ÏÀüÇ׿ø(¡­ù÷ê«).
  • conjugated antigen
    Á¢ÇÕÇ׿ø(ïÈùêù÷ê«).
  • core antigen
    ÄÚ¾îÇ׿ø
  • cross reactive antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • cross-reaction antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • cytokeratin antigen
    ¼¼Æ÷ °¢Áú Ç׿ø(á¬øà ÊÇòõ ù÷ê«)
  • cytokeratin antigen
    ¼¼Æ÷ °¢ÁúÇ׿ø
  • cytoskeletal antigen
    ¼¼Æ÷ °ñ°Ý Ç׿ø
  • delta antigen
    µ¨Å¸Ç׿ø
  • delta (¥ä) antigen
    µ¨Å¸Ç׿ø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
MultiODA multivariable optimal discriminant analysis
NAA N-acetyl aspartate; naphthaleneacetic acid; neutral amino acid; neutron activation analysis; neutrop...
NMPCA nonmetric principal component analysis
PAA partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas...
PCA para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
SSCA Single Strand Conformation Analysis
SSCP Single Strand Conformation Polymorphism analysis
SSCP Single Strand Conformational Polymorphism analysis
SSCP Single Stranded Conformational Polymorphism analysis
S.A.S Statistical Analysis System
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
T-dependent antigen An antigen that requires T helper cells in addition to appropriate B-cells. Most antigens are T-dependent.
(05 Mar 2000)
theta antigen A surface glycoprotein that is present on thymocytes of mice and rats.
(05 Mar 2000)
thymus-independent antigen An antigen that does not require T helper cell activation in order for the host's B-cells to be stimulated. Repeating polymers such as polysaccharides are examples of T-independent antigens.
(05 Mar 2000)
tissue polypeptide antigen Serological tumour marker composed of a molecular complex of cytokeratins 8, 18, and 19. It is used in the diagnosis and staging of bronchogenic carcinoma.
(12 Dec 1998)
tissue-specific antigen A heterogenetic antigen with organ specificity; e.g., in addition to species-specific antigen, kidney of one species contains antigen that is identical to that in kidney of other species.
Synonym: tissue-specific antigen.
(05 Mar 2000)
TL antigen <immunology> The mouse antigens coded for by the TLa complex, in normal animals only found on intrathymic lymphocytes, but also seen on leukaemic cells (hence, thymus leukaemia antigen) in certain forms of the disease in mice. The molecules have structures similar in some ways to Class I MHC products but are disulphide bonded tetramers of two 45 kD chains and two 12 kD chains of _2 microglobulin type.
(18 Nov 1997)
transplantation antigen <immunology> Any antigen that is antigenically active in graft rejection. In practice the major histocompatibility complex and the H Y antigens and to a lesser extent minor histocompatibility antigens.
(18 Nov 1997)
Epithelial membrane antigen <cell biology> Heavily glycosylated membrane glycoprotein. Encoded by the MUC 1 gene, has a molecular weight of around 300 kD, more than half of which is O linked glycan. There is a 69 residue cytoplasmic domain and the extracellular domain may extend hundreds of nanometres beyond the plasma membrane, the increased expression in carcinoma cells may reduce the adhesion and mask antigenic properties of the cells. Similar functions are ascribed to ASGP, epiglycanin and leucosialin.
(18 Nov 1997)
tumour-associated antigen Antigens that are highly correlated with certain tumour cells. They are not usually found, or are found to a lesser extent, on normal cells.
(05 Mar 2000)
tumour specific antigen <immunology, oncology> Antigen on tumour cells detected by cell-mediated immunity. For virus transformed cells TSTA (unlike T antigen) is found to differ for different individual tumours induced by the same virus. May consist of fragments of T antigens exposed at the cell surface.
(18 Nov 1997)
Js antigen sutter Blood Group
K antigen Capsular antigens of bacteria usually polysaccharide.
(18 Nov 1997)
Fas antigen <protein> Cell surface transmembrane protein (35 kD) that mediates apoptosis.
Has structural homology with TNF receptor and NGF receptor. May play a part in negative selection of autoreactive T-cells in the thymus.
(18 Nov 1997)
ki-67 antigen A cell cycle and tumour growth marker which can be readily detected using immunocytochemistry methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
(12 Dec 1998)
Km antigen Allotypic antigens that are present on human kappa immunoglobulin light chains.
Synonym: InV group antigen.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á